scholarly journals Glyoxylate Reductase/Hydroxypyruvate Reductase: A Novel Prognostic Marker for Hepatocellular Carcinoma Patients after Curative Resection

Pathobiology ◽  
2013 ◽  
Vol 80 (3) ◽  
pp. 155-162 ◽  
Author(s):  
Yinglian Pan ◽  
Runzhou Ni ◽  
Qingchun Deng ◽  
Xiaodong Huang ◽  
Yixin Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Marker ◽  
Curative Resection ◽  
Hydroxypyruvate Reductase ◽  
Glyoxylate Reductase

scholarly journals Peritumoral Cbl is a strong independent prognostic marker after curative resection of hepatocellular carcinoma

Oncotarget ◽  
2015 ◽  
Vol 6 (37) ◽  
pp. 40223-40234 ◽  
Author(s):  
Ju-Bo Zhang ◽  
Bo Zhang ◽  
Lei-Guo ◽  
Zhen-Hai Lin ◽  
Xiao-Qiang Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Marker ◽  
Curative Resection ◽  
Independent Prognostic Marker

scholarly journals ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection

2015 ◽  
Vol 47 (4) ◽  
pp. 853-861 ◽  
Author(s):  
Hye Won Hwang ◽  
Sang Yun Ha ◽  
Heejin Bang ◽  
Cheol-Keun Park
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Marker ◽  
Curative Resection

scholarly journals Corrigendum to “Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma”

2017 ◽  
Vol 2017 ◽  
pp. 1-1
Author(s):  
Xiao-Meng Dai ◽  
Tao Huang ◽  
Sheng-Li Yang ◽  
Xiu-Mei Zheng ◽  
George G. Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Marker ◽  
Curative Resection ◽  
Independent Prognostic Marker

scholarly journals The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jiarui Yang ◽  
Hao Liang ◽  
Kunpeng Hu ◽  
Zhiyong Xiong ◽  
Mingbo Cao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Conservative Treatment ◽  
Curative Resection ◽  
Postoperative Radiotherapy ◽  
Meta Analysis ◽  
Microvascular Invasion ◽  
Cochrane Library ◽  
Conservative Group ◽  
Adjuvant Therapies ◽  
Significant Difference

Abstract Background For patients with hepatocellular carcinoma (HCC) with microvascular invasion (MVI) after curative resection, the effects of various postoperative adjuvant therapies are not summarized in detail, and the comparison between the effects of various adjuvant therapies is still unclear. Thus, we collected existing studies on postoperative adjuvant therapies for patients with HCC with MVI after curative resection and analyzed the effects of various adjuvant therapies. Method We collected all studies on postoperative adjuvant therapy for patients with HCC with MVI after curative resection from PubMed, EMBASE, Cochrane Library and SinoMed ending on May 1, 2019. Overall survival (OS) and disease-free/recurrence-free survival (RFS) between each group were compared in these studies by calculating the pooled hazard ratio (HR) and 95% confidence interval (CI). All statistical analyses were assessed by two authors independently. Result A total of 13 studies were included in this study, including 824 postoperative adjuvant transarterial chemoembolization (pa-TACE) patients, 90 postoperative radiotherapy patients, 57 radiofrequency ablation (RFA)/re-resection patients, 16 sorafenib patients and 886 postoperative conservative treatment patients. The results showed that pa-TACE significantly improved OS and RFS compared with postoperative conservative treatment in patients with HCC with MVI after curative resection (HR: 0.64, 95% CI: 0.55–0.74, p < 0.001; HR: 0.70, 95% CI: 0.62–0.78, p < 0.001, respectively). There was no significant difference in OS between pa-TACE and radiotherapy in patients with HCC with MVI (HR: 1.75, 95% CI: 0.92–3.32, p = 0.087). RFS in patients with HCC with MVI after pa-TACE was worse than that after postoperative adjuvant radiotherapy (HR: 2.29, 95% CI: 1.43–3.65, p < 0.001). The prognosis of pa-TACE and RFA/re-resection in patients with MVI with recurrent HCC had no significant differences (HR: 0.65, 95% CI: 0.09–4.89, p = 0.671). Adjuvant treatments significantly improved the OS and RFS of patients compared with the postoperative conservative group (HR: 0.580, 95% CI: 0.480–0.710, p < 0.001; HR: 0.630, 95% CI: 0.540–0.740, p < 0.001, respectively). Conclusion Compared with postoperative conservative treatment, pa-TACE, postoperative radiotherapy and sorafenib can improve the prognosis of patients with hepatocellular carcinoma with microvascular invasion after curative resection. Postoperative radiotherapy can reduce the recurrence of patients with HCC with MVI after curative resection compared with pa-TACE.

Sign in / Sign up

Export Citation Format

Share Document